Humana (NYSE:HUM) Stock Rating Upgraded by StockNews.com

Humana (NYSE:HUMGet Rating) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday.

A number of other brokerages have also recently issued reports on HUM. UBS Group raised Humana from a “neutral” rating to a “buy” rating and raised their price objective for the company from $486.00 to $520.00 in a research note on Wednesday, April 13th. Truist Financial boosted their price objective on Humana from $460.00 to $490.00 in a research report on Thursday, April 7th. Deutsche Bank Aktiengesellschaft increased their price objective on Humana from $418.00 to $435.00 in a research note on Thursday, February 3rd. Sanford C. Bernstein lowered their price target on shares of Humana from $470.00 to $431.00 in a report on Tuesday, January 11th. Finally, Wells Fargo & Company cut their price target on shares of Humana from $529.00 to $452.00 in a report on Friday, January 7th. Seven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Humana has a consensus rating of “Buy” and an average target price of $484.55.

Shares of HUM stock opened at $458.69 on Wednesday. The business’s fifty day moving average is $436.89 and its 200 day moving average is $432.84. Humana has a 52-week low of $351.20 and a 52-week high of $475.44. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.62 and a current ratio of 1.62. The company has a market capitalization of $58.14 billion, a PE ratio of 20.23, a price-to-earnings-growth ratio of 1.40 and a beta of 0.94.

Humana (NYSE:HUMGet Rating) last released its quarterly earnings results on Wednesday, February 2nd. The insurance provider reported $1.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.23 by $0.01. Humana had a return on equity of 17.39% and a net margin of 3.53%. The business had revenue of $21.05 billion for the quarter, compared to the consensus estimate of $21.28 billion. During the same quarter last year, the business posted ($2.30) earnings per share. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. On average, sell-side analysts forecast that Humana will post 24.16 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Bell Investment Advisors Inc purchased a new position in shares of Humana during the third quarter valued at approximately $26,000. Spire Wealth Management bought a new stake in Humana during the fourth quarter valued at approximately $30,000. BerganKDV Wealth Management LLC grew its position in Humana by 885.7% during the fourth quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after buying an additional 62 shares during the period. Selective Wealth Management Inc. bought a new stake in Humana during the fourth quarter valued at approximately $35,000. Finally, Cordasco Financial Network grew its position in Humana by 32.0% during the third quarter. Cordasco Financial Network now owns 99 shares of the insurance provider’s stock valued at $39,000 after buying an additional 24 shares during the period. 92.96% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.